Sign in
4

Changes in Ownership

Mineralys Therapeutics, Inc. Filed Acc 0001933414-25-000014

Options or other derivatives

  • Chief Executive Officer acquired 570,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Congleton Jon Chief Executive Officer 2025-02-13 Grant or award · Stock Option +570,000 570,000 D: show line 1 in the form
Loading xslF345X05/wk-form4_1740441525.xml…